February 18, 2021 /
Multiple sclerosis (MS) is a condition that causes damage to the central nervous system.
85% of people diagnosed with MS have some form of relapsing MS, and everyone experiences the condition differently. This study is testing a once monthly investigational injection with Glatiramer Acetate Depot (GA Depot) to find out if it is safe and effective at reducing the rate of relapses and disease progression, leading to better health outcomes for those living with relapsing MS.
New MS research can’t move forward without research participants.
Click here to answer a few questions to see if you may be eligible to take part in this clinical trial.
It is important to note that the MS International Federation (MSIF) determined that Glatiramer Acetate (marketed as “Copaxone” as well as generic versions) is unlikely to have a negative impact on COVID-19 severity.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY
